Recs

2

New York Tag-Teams Merck

New York City residents and those who live upstate finally have something in common: They -- or at least their governments -- both think that Merck (NYSE: MRK  ) owes them a bunch of money.

The city and state of New York are suing Merck for allegedly defrauding Medicaid and other government agencies, by hiding problems related to its Vioxx painkilling drug. The suit says that the agencies paid millions of dollars for Vioxx that went to patients with heart conditions -- money that those agencies never would have spent had Merck disclosed to them that Vioxx raises the risk of heart attacks. Merck, of course, has countered that it couldn't disclose something it didn't even know until right before it pulled the drug off the market.

A couple of things have me puzzled about this lawsuit. First, what took them so long? I thought New Yorkers were supposed to be fast-paced, but Merck pulled Vioxx off the market almost three years ago. Other states, including Alaska, Louisiana, Mississippi, Montana, Texas, and Utah, filed similar suits more than a year ago.

Second, what are the governments going to do with the money they want back? They would have spent the money on other pain relievers, so I guess they could just hand it over to rival cox-2 inhibitor maker Pfizer (NYSE: PFE  ) -- or maybe to Novartis (NYSE: NVS  ) for its Prexige, which isn't even approved yet. You know, if Vioxx wasn't marketed, maybe Novartis would have developed the drug sooner...

All kidding aside, I'm not sure that one more lawsuit added onto the roughly 27,000 suits Merck currently faces will really make much difference. As long as the drugmaker remains able to fight those suits one at a time, it will be a long time before Merck has to pay out a dime.

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 537006, ~/Articles/ArticleHandler.aspx, 2/14/2012 1:14:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 hours ago Sponsored by:
DOW 12,874.04 72.81 0.57%
S&P 500 1,351.77 9.13 0.68%
NASD 2,931.39 27.51 0.95%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/13/2012 4:00 PM
MRK $38.11 Up +0.20 +0.53%
Merck & Co., Inc. CAPS Rating: ****
PFE $21.30 Up +0.25 +1.19%
Pfizer, Inc. CAPS Rating: ****
NVS $56.54 Up +0.65 +1.16%
Novartis CAPS Rating: *****

Advertisement